Comparative Pharmacology
Head-to-head clinical analysis: CLARITIN D versus CYPROHEPTADINE HYDROCHLORIDE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CLARITIN D versus CYPROHEPTADINE HYDROCHLORIDE.
CLARITIN-D vs CYPROHEPTADINE HYDROCHLORIDE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Loratadine is a long-acting tricyclic antihistamine with selective peripheral H1 receptor antagonism. Pseudoephedrine is a sympathomimetic amine that acts as a decongestant by stimulating alpha-adrenergic receptors in the respiratory tract mucosa, causing vasoconstriction.
Cyproheptadine is a potent antihistamine (H1 receptor antagonist) and antiserotonergic agent (5-HT2 receptor antagonist). It also exhibits weak anticholinergic and sedative properties. It blocks histamine-mediated vasodilation, increased capillary permeability, and pruritus, as well as serotonin-mediated effects on appetite and mood.
One tablet (5 mg loratadine/120 mg pseudoephedrine sulfate) orally every 12 hours; do not exceed 2 tablets in 24 hours.
4 mg orally three times daily; range 4-20 mg/day, not to exceed 0.5 mg/kg/day
None Documented
None Documented
Loratadine: 8-14 h (mean 11 h); desloratadine: 17-24 h (mean 21 h). Pseudoephedrine: 4-8 h (mean 6 h), prolonged in alkaline urine.
Terminal half-life approximately 8–16 hours in adults; may be prolonged in elderly or hepatic impairment.
Loratadine: 40% renal (metabolites), ~40% fecal; desloratadine: 33% renal, 66% fecal. Pseudoephedrine: 70-90% renal unchanged, 1-2% biliary.
Primarily renal (appreciable unchanged drug and metabolites); biliary/fecal elimination minor (<5%).
Category C
Category A/B
Antihistamine/Decongestant Combination
Antihistamine